Peptide Vaccine Against P32 Protein Protects Mice From Breast Cancer | Research

The takeaway

A multi-epitope peptide vaccine targeting the P32 protein, delivered via pulsed PBMCs with CpG adjuvant, induced protective anti-tumor immunity and reduced breast cancer tumor growth in mice.

Smaller tumors and prolonged survival
PBMC-based P32 peptide vaccine achieved comparable protection to DC-based delivery at lower cost and complexity

What the researchers found

F4 peptide from P32 protein delivered via CpG-adjuvanted PBMCs or DCs induced protective immune responses with smaller tumors and prolonged survival in a mouse breast cancer model, with PBMCs offering a simpler alternative to DCs.

Why it matters

Breast cancer remains a leading cause of cancer death worldwide. A simple, cost-effective peptide vaccine that can be prepared with PBMCs (avoiding the complexity of dendritic cell isolation) could make cancer immunotherapy more accessible.

The numbers in context

160 mice; 5 groups/peptide; increased IFN-γ, granzyme B, FasL, Caspase3; decreased Foxp3; smaller tumors; longer survival

How the study worked

160 BALB/c mice vaccinated in 5 subgroups per peptide (PBS, peptide alone, peptide+CpG, peptide+CpG+DCs, peptide+CpG+PBMCs). Immune responses: IFN-γ, granzyme B, FasL, Foxp3, Caspase3 by ELISPOT, ELISA, and gene expression. Tumor challenge with 4T1 cells.

Who was studied

160 BALB/c mice challenged with 4T1 breast cancer cells after peptide vaccination

What this study cannot tell us

Mouse model with transplanted tumor — may not reflect spontaneous human breast cancer. Single tumor cell line (4T1). Prophylactic rather than therapeutic vaccination. Specific epitope sequences not detailed in abstract.

How to read the evidence

Well-designed preclinical study with appropriate controls and multiple immune outcome measures. Pre-clinical evidence in a syngeneic tumor model.

When this study was published

Published in 2021, contributing to cancer vaccine development with a focus on accessible delivery methods.

The bigger picture

Most cancer vaccine research focuses on dendritic cell-based approaches, which are effective but expensive and complex. This study demonstrates that PBMCs — simpler and cheaper to obtain — can deliver peptide vaccines with comparable anti-tumor efficacy, potentially democratizing cancer immunotherapy.

Questions still open

Would P32 peptide vaccines be effective therapeutically against established tumors?
Is P32 a viable target in human breast cancer immunotherapy?
How does PBMC-based delivery compare to DC-based delivery long-term?

Common questions

What is a peptide cancer vaccine?

A peptide cancer vaccine uses small protein fragments from a cancer-associated protein (in this case P32) to train the immune system to recognize and attack cancer cells expressing that protein. The immune system's T cells learn to identify these peptide fragments and kill cancer cells displaying them.

Why is the PBMC approach significant?

Traditional cancer vaccines often use dendritic cells, which are expensive and complex to prepare. This study shows that PBMCs (peripheral blood cells that are easy to obtain from a simple blood draw) can deliver the peptide vaccine with comparable anti-tumor effectiveness, potentially making cancer vaccination more accessible and affordable.

Read the original research

Protective immune response against P32 oncogenic peptide-pulsed PBMCs in mouse models of breast cancer.

International immunopharmacology, 93, 107414

View on PubMed ↗Publisher’s paper ↗

Citation

Dehghan-Manshadi, Mahdi; Nikpoor, Amin Reza; Hadinedoushan, Hossein; Zare, Fateme; Sankian, Mojtaba; Fesahat, Farzaneh; Rafatpanah, Houshang. (2021). Protective immune response against P32 oncogenic peptide-pulsed PBMCs in mouse models of breast cancer.. International immunopharmacology, 93, 107414. https://doi.org/10.1016/j.intimp.2021.107414